Anemia in patients suffering from end-stage renal failure is currently treated with Erythropoiesis-Stimulating Agents (ESA). This treatment needs sufficient iron supplementation to avoid an inadequate dosage of ESA. Nowadays modern analytical instruments allow to accurately calculate the content of Hemoglobin (Hb) in reticulocytes (CHr), that can be used as a guide for prescribing patients with the appropriate amount of iron.
Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study / Capone, Domenico; Cataldi, Mauro; Viniguerra, Mauro; Mosca, Teresa; Barretta, Salvatore; Ragosta, ANNALISA ROSANNA; Sorrentino, Aniello; Vecchione, Alessandra; Barretta, Luca; Tarantino, Giovanni. - In: IN VIVO. - ISSN 0258-851X. - 31:4(2017), p. 709-712. [10.21873/invivo.11118]
Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study
CAPONE, DOMENICO;CATALDI, MAURO;RAGOSTA, ANNALISA ROSANNA;SORRENTINO, ANIELLO;TARANTINO, GIOVANNI
2017
Abstract
Anemia in patients suffering from end-stage renal failure is currently treated with Erythropoiesis-Stimulating Agents (ESA). This treatment needs sufficient iron supplementation to avoid an inadequate dosage of ESA. Nowadays modern analytical instruments allow to accurately calculate the content of Hemoglobin (Hb) in reticulocytes (CHr), that can be used as a guide for prescribing patients with the appropriate amount of iron.| File | Dimensione | Formato | |
|---|---|---|---|
|
in vivo 2017.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
81.83 kB
Formato
Adobe PDF
|
81.83 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
